Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8698883 | 1.00 | GBA1 (0.39) | GBA1ALDH1A1SMN1; SMN2RAB9AGAA | |
| SCHEMBL6238509 | 0.97 | — | — | |
| SCHEMBL7610524 | 0.92 | — | — | |
| SCHEMBL7610518 | 0.86 | — | — | |
| SCHEMBL6612099 | 0.85 | GBA1 (0.37) | GBA1ALDH1A1SMN1; SMN2RAB9AGAA | |
| SCHEMBL8429881 | 0.85 | GBA1 (0.37) | GBA1ALDH1A1SMN1; SMN2RAB9AGAA | |
| SCHEMBL8427828 | 0.83 | GBA1 (0.36) | GBA1ALDH1A1SMN1; SMN2RAB9AGAA | |
| SCHEMBL776553 | 0.83 | GBA1 (0.44) | GBA1ALDH1A1SMN1; SMN2RAB9AGAA | |
| SCHEMBL28418396 | 0.82 | GBA1 (0.34) | GBA1ALDH1A1SMN1; SMN2RAB9AGAA | |
| SCHEMBL8427539 | 0.81 | GBA1 (0.35) | GBA1ALDH1A1SMN1; SMN2RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106243100-A | Treatment alcohol use disorders, pain and the drug regimen of other diseases and method | VM生物医药公司 | 2016-12-21 | — | — | CN | claimed |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | V-BAC HOLDING CORP. (CA) | 2015-09-24 | — | — | US | claimed |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | claimed |
| EP-1663962-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORP (US) | 2007-08-22 | — | — | EP | claimed |
| JP-2007503392-A | — | — | 2007-02-22 | — | — | JP | claimed |
| EP-1663962-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | DENDREON CORPORATION (US) | 2005-03-10 | — | — | US | claimed |
| WO-2005020897-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2005-03-10 | — | — | WO | claimed |
| CN-111302926-B | Beta-diketone cerium (IV) compound and preparation and application thereof | 湖北固润科技股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-111302926-A | β -diketone cerium (IV) compound and preparation and application thereof | 湖北固润科技股份有限公司 | 2020-06-19 | — | — | CN | disclosed |
| EP-2894685-B1 | BENZOTHIENOBENZOTHIOPHENE DERIVATIVE, ORGANIC SEMICONDUCTOR MATERIAL, AND ORGANIC TRANSISTOR | DAINIPPON INK & CHEMICALS (JP) | 2018-10-31 | — | — | EP | disclosed |
| CN-104769735-B | Benzothiophene and benzothiophene derivative, organic semiconducting materials and organic transistor | DIC株式会社 | 2017-07-28 | — | — | CN | disclosed |
| US-9490433-B2 | Benzothienobenzothiophene derivative, organic semiconductor material, and organic transistor | DIC CORPORATION (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | V-BAC HOLDING CORP. (CA) | 2015-09-24 | — | — | US | disclosed |
| EP-0655992-B1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMA CO LTD (JP) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998007720-A1 | SUBSTITUTED 2-ARYLPYRIDINE AS HERBICIDE | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-26 | — | — | WO | disclosed |
| EP-0818512-A1 | Quinoline derivative and use of same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1998-01-14 | — | — | EP | disclosed |
| EP-0791570-A1 | Fluorenone derivatives, process for preparing the same and central or peripheral nerve degeneration repair and protective agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-27 | — | — | EP | disclosed |
| EP-0655992-A1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995000468-A1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | GBA1 3931/4885ALDH1A1 4716/4885SMN1; SMN2 4052/4885 |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | GBA1 4016/4885ALDH1A1 4724/4885SMN1; SMN2 4056/4885 |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | TRPC4, TRPC3, TRPC1 | GBA1 3061/4885ALDH1A1 4742/4885SMN1; SMN2 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.